These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 24052547)
1. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Bödör C; Grossmann V; Popov N; Okosun J; O'Riain C; Tan K; Marzec J; Araf S; Wang J; Lee AM; Clear A; Montoto S; Matthews J; Iqbal S; Rajnai H; Rosenwald A; Ott G; Campo E; Rimsza LM; Smeland EB; Chan WC; Braziel RM; Staudt LM; Wright G; Lister TA; Elemento O; Hills R; Gribben JG; Chelala C; Matolcsy A; Kohlmann A; Haferlach T; Gascoyne RD; Fitzgibbon J Blood; 2013 Oct; 122(18):3165-8. PubMed ID: 24052547 [TBL] [Abstract][Full Text] [Related]
2. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein. Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685 [TBL] [Abstract][Full Text] [Related]
3. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations. Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383 [TBL] [Abstract][Full Text] [Related]
4. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047 [TBL] [Abstract][Full Text] [Related]
5. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Okosun J; Bödör C; Wang J; Araf S; Yang CY; Pan C; Boller S; Cittaro D; Bozek M; Iqbal S; Matthews J; Wrench D; Marzec J; Tawana K; Popov N; O'Riain C; O'Shea D; Carlotti E; Davies A; Lawrie CH; Matolcsy A; Calaminici M; Norton A; Byers RJ; Mein C; Stupka E; Lister TA; Lenz G; Montoto S; Gribben JG; Fan Y; Grosschedl R; Chelala C; Fitzgibbon J Nat Genet; 2014 Feb; 46(2):176-181. PubMed ID: 24362818 [TBL] [Abstract][Full Text] [Related]
6. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860 [TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747 [TBL] [Abstract][Full Text] [Related]
8. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma. Nagy Á; Bátai B; Balogh A; Illés S; Mikala G; Nagy N; Kiss L; Kotmayer L; Matolcsy A; Alpár D; Masszi T; Masszi A; Bödör C Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32668764 [TBL] [Abstract][Full Text] [Related]
9. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. Julia E; Salles G Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777 [TBL] [Abstract][Full Text] [Related]
10. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430 [TBL] [Abstract][Full Text] [Related]
11. The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma. Barasch NJK; Liu YC; Ho J; Bailey N; Aggarwal N; Cook JR; Swerdlow SH Hum Pathol; 2020 Dec; 106():93-105. PubMed ID: 33045225 [TBL] [Abstract][Full Text] [Related]
12. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Huet S; Xerri L; Tesson B; Mareschal S; Taix S; Mescam-Mancini L; Sohier E; Carrère M; Lazarovici J; Casasnovas O; Tonon L; Boyault S; Hayette S; Haioun C; Fabiani B; Viari A; Jardin F; Salles G Blood Cancer J; 2017 Apr; 7(4):e555. PubMed ID: 28430172 [TBL] [Abstract][Full Text] [Related]
13. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Siddiqi IN; Friedman J; Barry-Holson KQ; Ma C; Thodima V; Kang I; Padmanabhan R; Dias LM; Kelly KR; Brynes RK; Kamalakaran S; Houldsworth J Mod Pathol; 2016 Jun; 29(6):570-81. PubMed ID: 26965583 [TBL] [Abstract][Full Text] [Related]
14. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications. van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871 [TBL] [Abstract][Full Text] [Related]
15. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Mottok A; Jurinovic V; Farinha P; Rosenwald A; Leich E; Ott G; Horn H; Klapper W; Boesl M; Hiddemann W; Steidl C; Connors JM; Sehn LH; Gascoyne RD; Hoster E; Weigert O; Kridel R Blood; 2018 Jan; 131(2):226-235. PubMed ID: 29122756 [TBL] [Abstract][Full Text] [Related]
16. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples. Saieg MA; Geddie WR; Boerner SL; Bailey D; Crump M; da Cunha Santos G Cancer Cytopathol; 2013 Jul; 121(7):377-86. PubMed ID: 23361872 [TBL] [Abstract][Full Text] [Related]
17. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Korfi K; Ali S; Heward JA; Fitzgibbon J Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467 [TBL] [Abstract][Full Text] [Related]
18. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772 [TBL] [Abstract][Full Text] [Related]
19. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Hellmuth JC; Louissaint A; Szczepanowski M; Haebe S; Pastore A; Alig S; Staiger AM; Hartmann S; Kridel R; Ducar MD; Koch P; Dreyling M; Hansmann ML; Ott G; Rosenwald A; Gascoyne RD; Weinstock DM; Hiddemann W; Klapper W; Weigert O Blood; 2018 Oct; 132(16):1695-1702. PubMed ID: 30126979 [TBL] [Abstract][Full Text] [Related]